MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Phase 4
Withdrawn
Conditions
Colitis, Ulcerative
Crohn Disease
Interventions
First Posted Date
2016-05-03
Last Posted Date
2020-10-27
Lead Sponsor
Takeda
Registration Number
NCT02760615
Locations
🇺🇸

WCCT, Cypress, California, United States

🇺🇸

QPS MRA, Miami, Florida, United States

N-of-1 Trials for Blood Pressure Medications in Adults

Early Phase 1
Completed
Conditions
High Blood Pressure
Hypertension
Interventions
First Posted Date
2016-04-20
Last Posted Date
2019-03-26
Lead Sponsor
Columbia University
Target Recruit Count
10
Registration Number
NCT02744456
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

A Controlled Trial of Losartan in Posttraumatic Stress Disorder

Not Applicable
Completed
Conditions
Posttraumatic Stress Disorder
Interventions
Drug: Placebo
First Posted Date
2016-03-15
Last Posted Date
2021-03-12
Lead Sponsor
University of California, San Diego
Target Recruit Count
149
Registration Number
NCT02709018
Locations
🇺🇸

George Washington University, Washington, District of Columbia, United States

🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

🇺🇸

New York University Langone Health, New York, New York, United States

and more 3 locations

Resveratrol's Effects in Diabetic Nephropathy

Early Phase 1
Completed
Conditions
Diabetic Nephropathy
Interventions
First Posted Date
2016-03-10
Last Posted Date
2017-10-05
Lead Sponsor
Shiraz University of Medical Sciences
Target Recruit Count
60
Registration Number
NCT02704494
Locations
🇮🇷

Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of

Losartan Effects on Emphysema Progression

Phase 4
Completed
Conditions
Emphysema
Interventions
Drug: Placebo
First Posted Date
2016-03-02
Last Posted Date
2022-06-01
Lead Sponsor
JHSPH Center for Clinical Trials
Target Recruit Count
220
Registration Number
NCT02696564
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

University of Florida College of Medicine, Jacksonville, Florida, United States

and more 25 locations

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

Phase 2
Completed
Conditions
Inflammation
Interventions
Dietary Supplement: Omega-3 fish oil
Other: Corn Oil (Fish oil Placebo)
Other: Cellulose Based (Losartan Placebo)
First Posted Date
2016-02-08
Last Posted Date
2024-05-07
Lead Sponsor
University of Florida
Target Recruit Count
289
Registration Number
NCT02676466
Locations
🇺🇸

Wake Forest University, Winston-Salem, North Carolina, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 2 locations

Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema

Phase 2
Completed
Conditions
Diabetic Macular Edema
Interventions
First Posted Date
2016-01-26
Last Posted Date
2016-07-06
Lead Sponsor
Tehran University of Medical Sciences
Target Recruit Count
57
Registration Number
NCT02663141
Locations
🇮🇷

Farabi Eye Hospital, Tehran, Iran, Islamic Republic of

A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan

Phase 3
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: Fimsartan 60mg~120mg
First Posted Date
2015-12-03
Last Posted Date
2022-05-25
Lead Sponsor
Boryung Pharmaceutical Co., Ltd
Target Recruit Count
351
Registration Number
NCT02620306
Locations
🇰🇷

Severance hospital, Seoul, Korea, Republic of

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

Phase 2
Suspended
Conditions
Stress Disorders, Post-Traumatic
Interventions
Procedure: Microneurography
Device: Transcutaneous Vagal Nerve Stimulation (tVNS)
Device: Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
Behavioral: Combat virtual reality video clip
Procedure: Handgrip Exercise
Procedure: Cold Pressor Test (CPT)
First Posted Date
2015-09-25
Last Posted Date
2025-03-05
Lead Sponsor
Emory University
Target Recruit Count
134
Registration Number
NCT02560805
Locations
🇺🇸

Atlanta VA Medical Center, Decatur, Georgia, United States

Influence of Aliskiren on Albuminuria After Kidney Transplantation

Not Applicable
Completed
Conditions
Albuminuria
Interventions
First Posted Date
2015-05-18
Last Posted Date
2015-05-18
Lead Sponsor
Medical University of Gdansk
Target Recruit Count
18
Registration Number
NCT02446548
Locations
🇵🇱

Medical University of Gdansk, Gdansk, Pomorskie, Poland

© Copyright 2025. All Rights Reserved by MedPath